Daniel R. Hart

2021

In 2021, Daniel R. Hart earned a total compensation of $1.3M as Chief Financial Officer at Peregrine Pharmaceuticals, a 60% increase compared to previous year.

Compensation breakdown

Bonus$116,112
Non-Equity Incentive Plan$310,624
Option Awards$315,054
Salary$423,698
Stock Awards$135,004
Other$48,846
Total$1,349,338

Hart received $423.7K in salary, accounting for 31% of the total pay in 2021.

Hart also received $116.1K in bonus, $310.6K in non-equity incentive plan, $315.1K in option awards, $135K in stock awards and $48.8K in other compensation.

Rankings

In 2021, Daniel R. Hart's compensation ranked 7,672nd out of 12,405 executives tracked by ExecPay. In other words, Hart earned more than 38.2% of executives.

ClassificationRankingPercentile
All
7,672
out of 12,405
38th
Division
Manufacturing
3,378
out of 5,494
39th
Major group
Chemicals And Allied Products
1,495
out of 2,369
37th
Industry group
Drugs
1,329
out of 2,090
36th
Industry
Pharmaceutical Preparations
980
out of 1,537
36th

Pay ratio

Daniel R. Hart's Pay$1,349,338
Median Employee's Pay$104,222
Pay Ratio

13

to 1

In 2021, the annual total compensation of Daniel R. Hart was $1,349,338.

The annual total compensation of the median employee at Peregrine Pharmaceuticals was $104,222.

The ratio of Daniel R. Hart's pay to the pay of median employee was therefore 13 to one.

Source: SEC filing on August 27, 2021.

Hart's colleagues

We found three more compensation records of executives who worked with Daniel R. Hart at Peregrine Pharmaceuticals in 2021.

2021

Nicholas Green

Peregrine Pharmaceuticals

Chief Executive Officer

2021

Mark Ziebell

Peregrine Pharmaceuticals

General Counsel

2021

Richard Hancock

Peregrine Pharmaceuticals

Chief Executive Officer

News

You may also like